Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy
MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy and safety of amlenetug in the treatment of Multiple System Atrophy (MSA)H. Lundbeck A/S (Lundbeck) today announced the advancement of the clinical development of amlenetug (Lu AF82422) for the treatment of MSA with the initiation of MASCOT, a randomized, double-blind, phase III trial. The trial builds on the encouraging results of the AMULET phase II trial showing consistent trend towards amlenetug slowing clinical progression in MSA patients despite the primary endpoint not meeting
Kristiansand, Norway – November 27, 2024 – Elkem ASA has secured EUR 1.8 million in funding from the European Union for the groundbreaking Elkem Sicalo® (Silicon production with carbon looping) project, which aims to eliminate all CO2 emissions from silicon production.Elkem, SINTEF and NORCE are completing the first pilot phase of Elkem Sicalo® at Elkem’s technology park in Kristiansand, Norway. The project entails capturing the carbon emitted from the silicon furnace and reusing it as a reductant in the silicon production process. The EU has now granted EUR 9.9 million in funding for the
